Company Executives Outline Growth Strategies and Expansions at the DCAT Member Company Announcement Forum

In this special issue of DCAT Value Chain Insights, we are providing information that would have been presented at the DCAT Member Company Announcement Forum at DCAT Week ’20. Originally scheduled to be held on March 23 in New York, these announcements were selected by the Announcement Oversight Task Force, as they present the latest major company news impacting the pharmaceutical manufacturing value chain. CEOs and senior executives from DCAT member companies outline their companies’ growth strategies by providing updates on key mergers and acquisitions and expansions with news from the following companies: Cambrex, Recipharm, Thermo Fisher Scientific, Lonza, SK pharmteco, Catalent, Biocon, CordenPharma, and WuXi STA. The individual news developments are outlined below.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

CDMOs/CMOs & Tariffs: The Next Move

By
The White House extended the deadline to impose reciprocal tariffs on most countries until August 1st. What is the impact on manufacturing & supply lines, and what may be next?

Mid-Year Review: New Drug Approvals—Up or Down?

By
With budgetary and staffing cuts at FDA, have approvals of new drugs slowed? DCAT Value Chain Insights looks at the numbers and key trends in new drug approvals thus far in 2025.

Cell and Gene Therapies: How is the Market Faring? 

By
Cell and gene therapies are a niche segment in the global bio/pharmaceutical market. What are leading products, and what are key developments thus far in 2025? 

Productivity, Wages, and AI: A Plus or Minus?

By
A recent PwC analysis examined the impact of productivity, wages, and overall value in industries with strong and limited exposure to AI. What did it find?